Tillomed Laboratories choose Mawdsleys as their distributor to hospitals
Tillomed Laboratories choose Mawdsleys as their distributor to hospitals 18th September 2017

Mawdsleys are delighted to be assisting Tillomed Laboratories in bringing their injectable products to market (September 2017). We will be distributing CMU contracted products to English hospitals and products with special prices to Scotland, Wales and Northern Ireland:

 

 

Description: Carmustine Injection Vial 100mg

Pack: 100mg

PIP Code: 7936438

EAN Code: 008902319061371

Description: Cidofovir Solution / Injection 375mg/5ml

Pack: 375mg/5ml

PIP Code: 6904312

EAN Code: 008902319061494

Description: Melphalan Injection Vial 50mg

Pack: 50mg

PIP Code: 7921141

EAN Code: 008902319061050

 

Tillomed Laboratories say about the new distribution agreement, “We are pleased to be working alongside Mawdsleys who are acknowledged as a market leader in hospital distribution, and we look forward to strengthening our partnership over the forthcoming years with new launches.”

 

With Mawdsleys you will benefit from:

 

– Industry-leading 22 days average stock holding

– EDI or online ordering

– Live stock levels, prices and invoices, as well as managing back orders, online

– No minimum order levels

– Reliable and accurate daily deliveries from your local depot

– Working together to make efficiency savings

 

Stock is available now (September 2017). Order from Mawdsleys through your normal preferred route i.e. EDI, through the Mawdsleys online ordering system, Mawdsleys Online, or by calling or faxing Customer Services.

 

Tillomed Laboratories product information is available by emailing medinfo@tillomed.co.uk

 

Should you have any queries, please contact your Mawdsleys Regional Hospital Account Manager. You may also contact Mawdsleys customer service on 0844 736 9016 or email info@mawdsleys.co.uk

 

Other latest news
https://www.mawdsleys.co.uk/news/mawdsleys-and-oncoscience-launch-a-named-patient-program-for-cimaher-nimotuzumab-in-the-uk-and-ireland/ thumbnail image Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher®

Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingdom (UK) and Ireland to obtain access to CIMAher® (Nimotuzumab) on an unlicensed basis for the treatment of various types of cancer.   Nimotuzumab has been approved for marketing in 25 different countries worldwide for a variety of…

Read more
https://www.mawdsleys.co.uk/news/mawdsleys-host-webinar-on-named-patient-programmes/ thumbnail image Mawdsleys Host Webinar on Named Patient Programmes

Mawdsleys is hosting a webinar to help people in the healthcare sector and pharmaceutical industry develop a deeper understanding of Named Patient Programmes. Participants of the webinar will hear how named patient programmes can be successfully implemented to treat patients who need a medicine that is not locally available to…

Read more